Argenx Gets Under Skin Of Rivals With Vyvgart Hytrulo Approval
Subcutaneous Formulation of Egartigimod Alfa Gets FDA OK
The US approval of a more convenient formulation of its myasthenia gravis therapy, Vyvgart, should cement its market position as well as change the definition of what being "well-controlled means for patients", Argenx hopes.
